3 gene therapy companies secure VC money; Novalis closes nearly $30 million fund
A European life sciences VC firm will invest in three more startups specializing in rare genetic diseases as a part of its Sofinnova Telethon Fund, the company announced Wednesday.
AAVantgarde Bio, Alia Therapeutics and Borea Therapeutics will receive seed funding worth a total of $7.1 million. The fund is dedicated to biotechs in Italy, and led by Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.